EST Sana Biotechnology (SANA) up 285% afterhours following type 1 diabetes study dataStay Ahead of the Market:Discover outperforming

First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection,

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43 rd Annual J.P.

BioUtah, the trade association, common voice, and flag bearer for Utah's life sciences industry, will participate in the 2025 J.P. Morgan 43rd Annual Healthcare Conference. BioUtah to co-host an RSVP-required reception on Sunday night,

LAS VEGAS, NV / ACCESSWIRE / / Alyea Therapeutics Corporation Inc. ("Alyea" or the "Company"), a subsidiary of Alt 5 Sigma Corporation (NASDAQ:ALTS), announced today its engagement in key events during the 43rd Annual J.